DDInter1040 DDInter782
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Letrozole {u} (Compound) resembles {v} (Compound) Bifonazole
Letrozole {u} (Compound) treats {v} (Disease) breast cancer
Letrozole {u} (Compound) binds {v} (Gene) CYP19A1
Letrozole {u} (Compound) upregulates {v} (Gene) KIAA0355
Letrozole {u} (Compound) downregulates {v} (Gene) ACAT2
Letrozole {u} (Compound) causes {v} (Side Effect) Mucosal dryness
Letrozole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Letrozole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phenobarbital
Letrozole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Estrone sulfate
Letrozole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Conivaptan
Letrozole (Compound) resembles Bifonazole (Compound)
Letrozole (Compound) treats breast cancer (Disease)
Letrozole (Compound) binds CYP19A1 (Gene)
Letrozole (Compound) upregulates KIAA0355 (Gene)
Letrozole (Compound) downregulates ACAT2 (Gene)
Letrozole (Compound) causes Mucosal dryness (Side Effect)
Letrozole may cause a minor interaction that can limit clinical effects when taken with Modafinil
Letrozole may cause a minor interaction that can limit clinical effects when taken with Phenobarbital
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan